AONN+ Conference Abstracts

One recent study revealed that lung cancer was the most common cancer among those uninsured.

This year, there are no accepted abstracts within this research category.

Acalabrutinib is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with CLL, including those with R/R CLL.

Two large phase 3 studies (COMBI-d [NCT01584648] and COMBI-v [NCT01597908]) evaluated the efficacy and safety of oral dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (D+T) as first-line therapy in patients (pts) with BRAF V600E- or V600K-mutant unresectable or metastatic cutaneous melanoma.

Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in endometrial carcinoma (EC) in a phase 1b/2 clinical trial (Study 111/KEYNOTE-146).

Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used androgen deprivation therapy (ADT) for prostate cancer (PCa).

Clinical pathways have increasingly been incorporated into cancer care, aiming to encourage high-quality, evidence-based care while minimizing costs; however, clinical pathways infrequently incorporate patient and family perspectives, limiting patient-centeredness and value for shared decision-making.

Ibrutinib is the only once-daily Bruton tyrosine kinase inhibitor that has shown significant progression-free survival (PFS) and overall survival (OS) benefits in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) across multiple randomized phase 3 studies.

Oncology nurse navigators and multidisciplinary models of care have been shown to improve outcomes for patients with cancer.

The UT Southwestern Cancer Genetics Program implemented a genetic patient navigator (GPN) to assess patients’ barriers to care, assist patients in identifying resources to increase compliance, promote healthy lifestyle education, and assist with coordination of cascade testing for at-risk relatives.